|
See related Myfortic tab information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Hong Kong: Zuellig/Macau: Four Star |
|
Contents |
Mycophenolate Na |
|
Indications |
Prophylaxis of acute transplant rejection in adults receiving allogenic renal transplants in combination w/ ciclosporin for microemulsion & corticosteroids.
Click to view Myfortic detailed prescribing infomation |
|
Dosage |
De novo patients Initial dose must be administered within 48 hr following transplantation. Recommended dose: 720 mg bd.
Click to view Myfortic detailed prescribing infomation |
|
Overdosage |
View Myfortic overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Pregnancy.
Click to view Myfortic detailed prescribing infomation |
|
Special Precautions |
Patients w/ rare hereditary deficiency of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) eg Lesch-Nyhan & Kelley-Seegmiller syndrome. Lactation. Childn. Elderly.
Click to view Myfortic detailed prescribing infomation |
|
Adverse Drug Reactions |
Malignancies & opportunistic infections in patients taking immunosuppressants. Very common: Leukopenia, diarrhoea. Common: Anaemia, thrombocytopenia, pyrexia, fatigue. Nausea, dyspepsia, vomiting, constipation; abdominal pain, distention & tenderness; flatulence, loose stools, gastritis. Abnormal liver function tests. Increased blood creatinine. UTI, herpes zoster, oral candidiasis, sinusitis, upper resp infection, gastroenteritis, herpes simplex, nasopharyngitis. Headache. Cough.
View ADR Monitoring Form |
|
Drug Interactions |
Aciclovir, Mg- & Al-containing antacids, azathioprine, cholestyramine & drugs that interfere w/ enterohepatic circulation, cyclosporin, ganciclovir, OCs, live vaccines.
View more drug interactions with Myfortic |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Storage |
View Myfortic storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Myfortic description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Myfortic mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Myfortic tablet |
|
Myfortic 180 mg x 120's |
 |
|
Myfortic 360 mg x 120's |
 |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Hong Kong: Zuellig
Macau: Four Star
|
|
|
|
